Re-Vana Therapeutics
PrivateLast Round
Series B
Jul 1, 2025
Total Funding Raised
$14.39M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Re-Vana Therapeutics operates in Healthcare & Life Sciences and is based in Belfast. Its latest recorded funding round was a Series A round in November 2022.
Re-Vana Therapeutics is a biotechnology company developing a sustained-release drug delivery platform for ophthalmic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical Devices
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Re-Vana Therapeutics Comparables
Compare Re-Vana Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ripple Therapeutics | 86% | |
| Everads Therapy | 82% | |
| Vinci Pharmaceuticals | 79% |
For institutional investors. Book with your work email.
Re-Vana Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 1, 2025 | ||||
| Series A | Nov 30, 2022 | ||||
| Grant | May 1, 2022 | ||||
| Pre-Series A | Jun 2, 2020 | ||||
| Grant | Sep 1, 2019 | ||||
Seed | Nov 27, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Re-Vana Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| QUBIS | Seed, Pre-Series A, Series A |
| Invest Northern Ireland | Seed |
| Innovate UK | Grant |
| Clarendon Fund Managers | Seed, Pre-Series A, Series A |
| Innovate UK | Grant |
| Techstart Ventures | Seed, Pre-Series A, Series A |
| Visionary Ventures | Pre-Series A, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 45% MoM.
- Jun 20, 2026
Monthly visitors increased 69% MoM.
For institutional investors. Book with your work email.
Re-Vana Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Re-Vana Therapeutics's valuation, stock price, and market status.
Is Re-Vana Therapeutics a public or private company?
Re-Vana Therapeutics is a private company.
What is the current stock price of Re-Vana Therapeutics?
Re-Vana Therapeutics is a private company, so its shares have no public market price. Caplight tracks Re-Vana Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Re-Vana Therapeutics worth (valuation)?
Valuation information for Re-Vana Therapeutics is not publicly available.
Can I buy Re-Vana Therapeutics stock?
Re-Vana Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Re-Vana Therapeutics's last funding round?
Re-Vana Therapeutics's most recent funding round was Series B on July 1, 2025.
Who are the main investors in Re-Vana Therapeutics?
Key investors in Re-Vana Therapeutics include Visionary Ventures, ExSight Ventures.
Will Re-Vana Therapeutics IPO soon?
No public IPO plans have been announced for Re-Vana Therapeutics.
How can I track Re-Vana Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Re-Vana Therapeutics's shares on secondary markets.